Related Experiment Video
Updated: Aug 29, 2026

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
Published on: March 3, 2014
Pharmacology and immunology of botulinum toxin type A
1Allergan Inc., 7575 Dupont Drive, Irvine, CA 92612, USA. Aoki_Roger@Allergan.com
Abstract:
The utility of botulinum neurotoxins as therapeutic and esthetic agents depends on their ability to inhibit neurotransmitter release from selected neurons, remain localized at the site of injection, and evade the body's immunologic defenses. The clinical correlates of these actions, respectively, are efficacy, safety, and a low rate of antibody formation. These properties have long formed the basis for the use of botulinum toxin type A (BTX-A) in the treatment of movement disorders such as focal dystonias, spasticity, and cerebral palsy and, more recently, in the treatment of glabellar lines--all of which are characterized by excessive muscle activity.
More Related Videos
Related Concept Videos
Botulism
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Tetanus
Bacterial Toxins
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Although all competitive neuromuscular blockers are designed...
Neuromuscular Junction And Blockade

